Century Therapeutics (NASDAQ:IPSC) Upgraded by Zacks Investment Research to Hold

Century Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Century Therapeutics Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Century Therapeutics (NASDAQ:IPSC) Upgraded by Zacks Investment Research to Hold

Does Earnings Surprise History Hold Any Clue for Century Therapeutics (NASDAQ:IPSC)

Earnings results for Century Therapeutics , Analyst Opinion on Century Therapeutics , Earnings and Valuation of (NASDAQ:IPSC), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Does Earnings Surprise History Hold Any Clue for Century Therapeutics (NASDAQ:IPSC)